arrow
H

Hervé Bonnefoi

université de bordeaux ufr sciences médicales
H指数:55
被引数:2.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial

基于基因组分级指数的高龄(≥70岁)高风险乳腺癌患者辅助化疗联合内分泌治疗与单纯辅助内分泌治疗的比较(ASTER 70s):一项随机III期临床试验

2025-07-310
PRE
Prognostic value of EndoPredict test in patients with hormone receptorpositive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial
2024-05-010
OAAI
Patient-reported outcomes in high-risk HR+ /HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib within the randomized PENELOPEB study
2024-01-012
PRE
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial
2023-11-025
OAAI
Machine learning-based characterization of tumor-immune microenvironment at a spatial and multiplexed resolution in early breast cancer: A sub-study of the EORTC 10994/BIG 1-00 randomized phase III trial with long-term follow-up

早期乳腺癌中基于机器学习的肿瘤免疫微环境的空间和多重分辨率表征: EORTC 10994/BIG 1-00随机III期试验的长期随访子研究

2023-10-010
OA
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
2023-04-0115
OAAI
Immunohistochemical markers and determinants of clinical response in the Penelope-B trial
2023-03-010
PRE
Patients' selection of daily timing of oral intake of adjuvant hormonotherapy (HT) and everolimus (EVE) for high risk early breast cancer in the UCBG-UNIRAD phase III trial
2023-03-010
PRE
Outcome analysis of HER2-zero or HER2-low hormone receptor-positive (HR plus ) breast cancer patients - characterization of the molecular phenotype in combination with molecular subtyping
2023-03-012
PRE
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial
2022-09-053
OAAI
Primary endpoint results of SYNERGY, a randomized phase II trial, first-line chemo-immunotherapy trial of durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab in patients with advanced or metastatic triple-negative breast cancer (TNBC)
2022-09-016
OAAI
Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)
2022-09-016
OAAI
Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib
2022-02-150
PRE